2020
DOI: 10.3390/jcm9103361
|View full text |Cite
|
Sign up to set email alerts
|

Bone Loss, Osteoporosis, and Fractures in Patients with Rheumatoid Arthritis: A Review

Abstract: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. Compared with a matched population, RA patients with fractures have more common risk factors of osteoporosis and fragility fractures but also risk factors resulting from the disease itself such as duration, intensity of the inflammation and disability, and cachexia. The inflammatory reaction in the synovium results in the production of numerous cytokines (interleukin-1, interleukin-6, tumor necr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
47
0
3

Year Published

2021
2021
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 57 publications
(51 citation statements)
references
References 65 publications
1
47
0
3
Order By: Relevance
“…Their levels seem to correlate with the amount of body fat and fall in response to weight loss [ 38 ]. TNF-a and IL-1 have a significant role in the inflammation-induced bone loss [ 39 ]. Still, in our ERA patients, the effect of inflammation on bone mass was not observed yet, probably due to the early course of RA disease.…”
Section: Discussionmentioning
confidence: 99%
“…Their levels seem to correlate with the amount of body fat and fall in response to weight loss [ 38 ]. TNF-a and IL-1 have a significant role in the inflammation-induced bone loss [ 39 ]. Still, in our ERA patients, the effect of inflammation on bone mass was not observed yet, probably due to the early course of RA disease.…”
Section: Discussionmentioning
confidence: 99%
“…In RA, the peripheral joints suffer from chronic inflammatory reactions [ 1 ]. This inflammatory reaction within the joint synovium leads to the production of multiple cytokines (tumor necrosis factor, interleukins-1, interleukin-6(IL-6)), resulting in activation of osteoclast that can mediate bone destructions [ 8 ]. Also, the inflammation in the joints increases bone absorption and makes the patient susceptible to bone loss and osteoporosis development [ 9 ].…”
Section: Reviewmentioning
confidence: 99%
“…Until now, there are no anti-resorbing drugs that can arrest or change the progression of RA-related bone erosions, as erosions result from non-osteoclast effect mechanisms [ 3 ]. But we can decrease osteoporosis development and bone loss in RA patients by using anti-inflammatory treatment, including DMARDs, which could reduce joint inflammation and decrease the rate of bone loss in RA patients [ 8 , 29 ]. It is better to use corticosteroids for the short term and the lowest dose possible [ 29 , 12 ].…”
Section: Reviewmentioning
confidence: 99%
“…Looking more in depth to these inflammatory diseases, some of them, such as RA, are characterized by great production of numerous cytokines (interleukin-1, interleukin-6, tumor necrosis factor) in the synovium that, in turn, activate osteoclasts and mediate cartilage and bone destruction of the joints, with a systemic effect leading to generalized bone loss [ 86 ]. Besides osteoclasts, immune cells including macrophages, mastocytes, dendritic cells, monocytes, plasma cells and B, T helper 1 (Th1), and 17 (Th17) lymphocytes, actively participate in tissue resorption [ 87 , 88 ].…”
Section: Role Of Purine Enzymes In Bone Inflammatory Conditionsmentioning
confidence: 99%